Abacavir/Lamivudine/Zidovudine (Trizivir)

The Latest

The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir?

The 8th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, offered up considerable new information on antiretroviral chemotherapy. One important study conducted by Josep Mallolas and colleagues in Barcelona, Spain, de...

By Mark Wainberg, Ph.D.

Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads

Poor zidovudine/lamivudine/abacavir (AZT/3TC/ABC, Trizivir). This was the first fixed-dose combination for HIV-infected patients and its convenient, one-pill, twice-daily dosing raised the flag for low-pill burden and triple-drug coformulation treatm...

By Benjamin Young, M.D., Ph.D.

Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy

Several treatment strategies have been designed to deal with patients whose first regimen is failing. Some of the strategies considered include:

an intensification approach in which a single drug is added to a marginally failing regimen in an attemp...

By Edwin DeJesus, M.D.

Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations

In the beginning, there was zidovudine (AZT, Retrovir). As the first antiretroviral drug approved for the treatment of HIV, its benefits during the early years of the epidemic were incalculable. However, zidovudine's use also had at least one downsid...

By Mark Wainberg, Ph.D.

Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance

Background

"Induction maintenance" is a treatment strategy that uses a more potent regimen initially and drops back to a less potent (and hopefully less toxic) regimen after the initial response. It is modeled on cancer chemotherapy, which has been ...

By Frank S. Rhame, M.D.

We Want Our Trizivir!

I've never seen so many doctors so reluctant to accept the results of a clinical trial. Everyone wanted so badly for Trizivir to show stellar results.

As three medications in one tablet taken twice a day, Trizivir's easy-to-take, easy-to-tolerate ...

By Enid Vazquez for Positively Aware

Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads

How can we construct the best, most potent drug regimens for the treatment of HIV? Conventional approaches utilize three-drug regimens that employ two nucleoside reverse transcriptase (NRTI) medications with one other drug -- either a protease inhibi...

By Benjamin Young, M.D., Ph.D.

Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy

This summer the results of ACTG 5095 were presented at The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris (click here for a summary), after being widely disseminated in the spring. ACTG 5095 showed that the combi...

By Andrew T. Pavia, M.D.

Another Look at Induction Maintenance Therapy

Induction of Antiretroviral-Naive HIV-Infected Subjects With Trizivir (TZV) and Sustiva (EFV) for 48 Weeks (ESS40013) (Oral 42) Authored by M. Markowitz, J. Lang, E. DeJesus, C. Hill-Zabala, E.R. Lanier, Q. Liao, K. Pappa, M. Shaefer

Induction...

By Andrew T. Pavia, M.D.

Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T

Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Trizivir (TZV), Combivir (COM)/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV (Poster 709) Authored by P. Kumar, A. Rodriguez-French, M. Thompson, K. Tashima, P. Wannam...

By Timothy Wilkin, M.D., M.P.H.